Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:56:28.359Z.
Consensus retrieved: 2026-10-06T10:34:52.460Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:56:28.359Z.
Quote observation: 2026-10-06T14:55:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1b199ac63604ed67463567be6e31784e7c30cd10ce6e12a6b441e61f1537d336
Forward PE Ratio (N/A) = Dated Quote Price ($34.24) / Consensus Forward EPS ($-1.27)
FORWARD PE RATIO
N/A
Castle Biosciences, Inc.
Market Cap
$1.05B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Castle Biosciences, Inc. (CSTL) | $1.05B | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.04B | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | N/A |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.03B | 16.67 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | 5.36 |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A |
| IRadimed Corporation (IRMD)vs › | $1.09B | 40.25 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $996.75M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $34.24, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.27 | $-1.29 – $-1.24 | 6 | n/m |
| 2027-12-31 | $-0.94 | $-0.95 – $-0.92 | 6 | n/m |
| 2028-12-31 | $-0.40 | $-0.97 – $0.10 | 6 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
